International Journal of Technology Assessment in Health Care最新文献

{"title":"A systematic literature review (SLR) on the adoption of artificial intelligence-assisted SLRS: implications for health technology assessments.","authors":"Seye Abogunrin, Yifei Liu, Clarissa Higuchi Zerbini","doi":"10.1017/S0266462326103535","DOIUrl":"10.1017/S0266462326103535","url":null,"abstract":"<p><strong>Objectives: </strong>Systematic literature reviews (SLRs) are essential for evidence synthesis in healthcare decision making, including health technology assessment (HTA), but their time and resource demands are substantial. Artificial intelligence (AI) may enhance efficiency of conducting SLRs, but its acceptance by HTA bodies remains underexplored. This SLR quantifies published health-related SLRs reporting AI use, identifies AI tools used at each SLR stage, and evaluates HTA guidance on AI in evidence synthesis.</p><p><strong>Methods: </strong>We searched Embase, Medline, and the Cochrane Library (up to 9 September 2025), supplemented by hand searches and reviews of HTA agency websites. Titles and abstracts were screened in Rayyan by a single reviewer, with full-text review confirming eligibility. Data were extracted and synthesized narratively along key themes.</p><p><strong>Results: </strong>In total, 112 studies covering 111 unique SLRs were identified, reporting 134 implementations of 45 unique AI tools (29 publicly available; 16 custom-built). AI use has risen since 2013 and was most frequently applied during title and abstract screening (88 of the 134 implementations). Human oversight remained essential, with no fully autonomous AI reported. Three HTA agencies (CDA-AMC, IQWiG, NICE), EUnetHTA, JBI and Cochrane have provided guidance, indicating the formal integration of AI into HTA processes.</p><p><strong>Conclusions: </strong>This SLR provides a quantitative overview of AI use in health-related SLRs and current HTA guidance. These findings may inform development of clearer methodological recommendations and support integration of AI-assisted evidence synthesis in HTA submissions. Further research and policy development are needed to optimize its role in evidence synthesis and healthcare decision making.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e29"},"PeriodicalIF":3.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building capacity for medical device assessment: online training for Ukrainian experts.","authors":"Olena Filiniuk, Antonio Migliore, Rossella Di Bidino, Nicola Vicari, Rebecca Kohler, Rabia Sucu","doi":"10.1017/S026646232610350X","DOIUrl":"10.1017/S026646232610350X","url":null,"abstract":"<p><p>As Ukraine works to modernize its healthcare system and align with international standards, integrating health technology assessment (HTA) into the national decision-making process has become a strategic priority. While HTA practices for pharmaceuticals have advanced, substantial gaps persist in the evaluation of medical devices (MDs), which require distinct methodological approaches given their characteristics. This article presents the rationale, development, implementation, and results of a comprehensive online training program aimed at building national capacity in the MD assessment. The program targeted 71 Ukrainian professionals with prior experience in pharmaceutical evaluation but limited exposure to MD. Through 40 hours of live online sessions delivered from September to December 2024, the course emphasized interactive learning, contextual adaptation, and international best practices. Assessments showed significant knowledge gains, with 87 percent of participants completing the program successfully. The initiative demonstrates that targeted, competency-based training can enhance national HTA capacity and may serve as a model for other transitioning healthcare systems.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e22"},"PeriodicalIF":3.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengthening health technology assessment (HTA) in the European Union: insights from Slovenia's implementation journey.","authors":"Katarina Beravs-Bervar, Wim Goettsch, Iñaki Gutierrez-Ibarluzea, Adam Skali, Alric Rűther, Iga Lipska, Eva Turk","doi":"10.1017/S0266462325103383","DOIUrl":"10.1017/S0266462325103383","url":null,"abstract":"<p><strong>Introduction: </strong>Slovenia has engaged with Health Technology Assessment (HTA) for over two decades, but its system remains fragmented and underdeveloped. Until recently, responsibilities for evaluating health technologies were dispersed across multiple institutions without a central coordinating body or standardized methodology. Medicinal products have been subject to structured evaluation through the Health Insurance Institute of Slovenia, while other health technologies, including medical devices, diagnostics, and preventive interventions, have followed less consistent pathways under the Ministry of Health. The adoption of the European Union Health Technology Assessment Regulation), entering into force in January 2025, has provided new impetus for reform, requiring Slovenia to designate a national HTA body to participate in joint clinical assessments and align national processes with EU standards.</p><p><strong>Methods: </strong>A mixed-methods analysis combining a narrative overview of HTA in Slovenia with findings from two multi-stakeholder workshops held in 2025. These workshops, which convened Slovenian and international experts, policymakers, clinicians, and patient representatives, explored opportunities and challenges for developing a robust HTA framework.</p><p><strong>Results: </strong>Key findings highlight the need to strengthen methodological capacity, introduce systematic stakeholder engagement, ensure transparency, and integrate real-world evidence into decision-making. Particular emphasis was placed on expanding HTA to medical devices, diagnostics, and digital health technologies, and on anticipating future innovations such as artificial intelligence.</p><p><strong>Conclusions: </strong>Slovenia now stands at a pivotal juncture. Establishing a central HTA body with a clear legal mandate, building national expertise, and leveraging regional and European collaboration is essential to creating a transparent, evidence-based, and patient-centred HTA system.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e23"},"PeriodicalIF":3.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HTA submission strategies and their associations with rollout times and type of HTA recommendation in Australia and Canada.","authors":"Belen Sola-Barrado, Ting Wang, Neil McAuslane","doi":"10.1017/S0266462326103511","DOIUrl":"10.1017/S0266462326103511","url":null,"abstract":"<p><strong>Objectives: </strong>Australia and Canada have parallel submission processes allowing companies to submit dossiers to the respective health technology assessment (HTA) body before marketing authorization is issued, aiming to provide more timely access to drugs. This study investigated the associations of submission strategies with new active substance (NAS) rollout times and HTA recommendations.</p><p><strong>Methods: </strong>This retrospective observational study analyzed HTA appraisals by the Pharmaceutical Benefits Advisory Committee (PBAC) and Canada's Drug Agency (CDA-AMC) for NASs that received their first HTA recommendation between 2019 and 2023. Regulatory and HTA dates were sourced from public records. We implemented logistic regression to examine associations of HTA recommendation (optimal vs non-optimal). Linear regression was used to test associations of rollout time. Models were adjusted for submission sequence, country, therapeutic area, expedited review, conditional review, top R&D spenders, and year of HTA recommendation.</p><p><strong>Results: </strong>229 HTA appraisals (126/229 parallel) were included. Parallel submissions were associated with a 14.0-month shorter rollout time compared to sequential submissions (<i>p</i> < 0.001). Rollout times in Canada were 6.0 months longer than those in Australia. Parallel submissions were associated with higher odds of receiving an optimal recommendation compared to sequential submissions (OR: 2.2; 95 percent CI: 1.2-4.2; <i>p</i> = 0.013). The odds of obtaining an optimal first HTA recommendation were higher in Canada than in Australia.</p><p><strong>Conclusions: </strong>NASs following parallel submission showed faster rollout times than those following traditional sequential submission. Moreover, parallel submissions were associated with higher odds of receiving an optimal recommendation. These findings highlight the value of aligning regulatory and HTA processes.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e20"},"PeriodicalIF":3.0,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12964150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146142327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of published mini and rapid health technology assessments reports: a cross-sectional analysis.","authors":"Sharon McLaughlin, Aanisa Abeer, Melissa K Sharp, Kieran A Walsh, Cassandra Nemzoff, Sheilagh Foley, Ed Clifton, Michelle Flood, Susan Spillane, Patricia Harrington, Conor Teljeur, Michelle O'Neill, Susan M Smith, Máirín Ryan, Barbara Clyne","doi":"10.1017/S0266462326103493","DOIUrl":"10.1017/S0266462326103493","url":null,"abstract":"<p><strong>Objectives: </strong>While rapid health technology assessments (HTA) are important for decision makers, there is no universally accepted definition or standardized methods. The objective of this study was to analyze the content and conduct of published rapid and mini-HTA reports.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of rapid and mini-HTA reports identified from the International HTA Database (2014-April 2024) and supplementary searches of HTA agency websites. We extracted descriptive data on rapid HTA products; specifically, which traditional HTA domains were included or omitted, evidence synthesis methods, and approaches to interest-holder (formerly known as stakeholder) engagement. Data analysis was conducted in Stata.</p><p><strong>Results: </strong>We included 203 rapid HTA reports. Most frequently included HTA domains were clinical effectiveness (99 percent) and safety (82.3 percent). Legal aspects (12.3 percent) and budget impact analyses (10.8 percent) were less frequently reported. Across reports reviewing clinical effectiveness (n = 201), generic literature searches were the most predominantly self-reported evidence synthesis method (37.8 percent), with updates (1.5 percent) and overviews (2 percent) of systematic reviews less common. Cost-utility analyses were the most commonly self-reported form of economic evaluation (36.2 percent). Additionally, public consultations (68 percent) were the most commonly reported ways to engage with interest holders.</p><p><strong>Conclusion: </strong>Our analysis highlights variations across rapid HTA reports and will contribute to wider research aiming to establish a clearer definition and framework of rapid HTAs and inform when and how rapid HTAs are performed. Clearer reporting and justification of simplifications in rapid HTA reports are needed.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e18"},"PeriodicalIF":3.0,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12964152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to the application of Health Technology Assessment (HTA) results: the case of COVID-19 vaccine deployment in Ghana.","authors":"Brian Adu Asare, Emmanuella Abassah-Konadu, Sarah Ama Kafui Okine, Ivy Amankwah, Desmond Dzidzornu Otoo, Hannah Asante, Saviour Yevutsey, Maxwell Ayindenaba Dalaba, Mustapha Immurana, Matilda Aberese-Ako, Joycelyn Azeez, Edith Enyonam Gavor, Martha Gyansa-Lutterodt, Evelyn Ansah, Tuoyo Okorosobo, Olumide Ogundahunsi, Abraham Hodgson, Seth Owusu Agyei, Margaret Gyapong","doi":"10.1017/S0266462325100342","DOIUrl":"10.1017/S0266462325100342","url":null,"abstract":"<p><strong>Objectives: </strong>Health Technology Assessment (HTA) guides healthcare decision-making, while Implementation Research (IR) addresses challenges in operationalizing these decisions. The SAVING (Sustainable Access and Delivery of New Vaccines in Ghana) Consortium aims to enhance health intervention delivery in Ghana, focusing on HTA evidence. This study identifies barriers to the application of HTA-related evidence (cost analysis) in coronavirus disease 2019 (COVID-19) vaccine deployment in Ghana.</p><p><strong>Methods: </strong>This qualitative exploratory study purposively selected 12 key stakeholders with high interest and power relating to COVID-19 vaccine deployment in Ghana. Through in-depth interviews, seven stakeholders from diverse sectors contributed insights into barriers to the application of HTA-related evidence. Thematic analysis was conducted with narrative reporting supported by direct quotes for substantiation.</p><p><strong>Results: </strong>Six main barriers were identified: (1) timing and access to HTA reports, (2) technical complexities, (3) relevance of content, (4) political considerations and power dynamics, (5) health system fragmentation, and (6) poor responsiveness of decision-makers to research. Proposed solutions include engaging political decision-makers continuously, simplifying technical reports, aligning report content with policymakers' needs, reducing political considerations, enhancing capacity building, fostering health system cohesion, and improving responsiveness to research.</p><p><strong>Conclusions: </strong>HTA is vital for informed healthcare decisions. However, technical complexity, relevance of content, inappropriate timing, and lack of access to HTA reports, among other barriers, prevent the uptake of HTA findings. Continuous and improved engagement between HTA producers and policymakers, along with rapid production of HTA, has the potential to improve the uptake of HTA findings, even during public health emergencies.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e17"},"PeriodicalIF":3.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovating HTA: a call for capacity building and standardization.","authors":"Diana M J Delnoij, Dalia M Dawoud, Jamie Elvidge, Zoltan Kaló, Saskia Knies, Bertalan Németh, Wim Goettsch","doi":"10.1017/S0266462326103456","DOIUrl":"10.1017/S0266462326103456","url":null,"abstract":"<p><strong>Objectives: </strong>New technologies are being developed in a context of scarcity. Health technology assessment (HTA) aims to support decision makers in providing equitable and affordable access to effective innovations. This study aims to summarize the policy-related findings of a Horizon2020 project on innovating HTA methods and discuss their implications for the governance of HTA in Europe.</p><p><strong>Methods: </strong>A thematic analysis of policy-oriented papers (<i>n</i> = 18) from the Next Generation Health Technology Assessment (HTx) project was carried out to summarize challenges and solutions. Subsequently, via an online survey and in a 2-day meeting, European and global stakeholders (<i>n</i> = 21) were invited to comment on these solutions and to prioritize future strategies.</p><p><strong>Results: </strong>Reported challenges included a lack of access to standardized data, differences in evidentiary needs, existing policy structures, and a lack of capacity and knowledge. Suggested solutions were capacity building, national and international dialogues, standardization, and increased European collaboration. Stakeholders had different expectations with respect to the likely success of these solutions.</p><p><strong>Conclusion: </strong>Innovation of HTA requires alignment of evidentiary needs through dialogues, standardization through increased European collaboration, and capacity building. However, without additional investments in personnel capacity, HTA agencies must still prioritize some activities at the expense of others. Furthermore, although European collaboration is important, global alignment might be required to enforce standardization.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":"42 1","pages":"e8"},"PeriodicalIF":3.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12902166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146063524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Horizon scan of the clinical development landscape of biosimilar products in the UK and EU.","authors":"Amy Hussain, Ross Fairbairn, Sarah Khalid Khan","doi":"10.1017/S0266462326103468","DOIUrl":"10.1017/S0266462326103468","url":null,"abstract":"<p><strong>Objectives: </strong>Biosimilars are biological medicines highly similar to an authorized reference medicine, offering substantial cost savings and increased treatment access. Despite the regulatory framework in the UK and EU facilitating their approval, the biosimilar landscape remains small compared to small-molecule drugs. This study provides a horizon scanning overview of the current biosimilar landscape, procured through horizon scanning activities.</p><p><strong>Methods: </strong>Data were sourced from ClinicalTrials.gov and the EU Clinical Trials Register, scanned monthly to identify innovative medicines in clinical development. We included biosimilars identified through horizon scanning from April 2017 to February 2025. Supplementary data were collected from the European Medicines Agency to ascertain approval status, and additional clinical trial information was manually extracted from relevant registries.</p><p><strong>Results: </strong>We identified 156 unique biosimilars developed across 174 clinical trials, with sixty-four approved by the MHRA and seventy-eight by the European Medicines Agency. Adalimumab, bevacizumab, and denosumab were the reference products with the most biosimilars in development. Most biosimilar trials were at phase III. There are seventy-one biosimilars in active development.</p><p><strong>Conclusions: </strong>The development landscape of biosimilars in the UK and EU show high activity levels. Continuous improvements in horizon scanning methods and regulatory frameworks are essential to support the timely adoption of biosimilars, maximizing their benefits for healthcare systems.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e14"},"PeriodicalIF":3.0,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing hospital-based health technology and impact assessments: institutionalizing strategic decision-making in innovation adoption.","authors":"Hao Yi Tan, Joshua Kuan Tan, Xiaohui Xin, Ruban Poopalalingam, Kenneth Kwek, Julian Thumboo, Mariam Krikorian Atkinson","doi":"10.1017/S026646232510336X","DOIUrl":"10.1017/S026646232510336X","url":null,"abstract":"<p><strong>Objectives: </strong>Hospitals are at the front line of adopting new health technologies, yet decision-making is often hampered by insufficient evidence, limited context, and misaligned priorities. Hospital-based health technology assessment (HB-HTA) provides a structured mechanism to evaluate innovations at the institutional level. However, published accounts of HB-HTA implementation remain scarce, particularly in Asian contexts.</p><p><strong>Methods: </strong>We describe Singapore General Hospital's (SGH) approach to institutionalizing HB-HTA through a three-pronged strategy: (1) structured two-page narrative proposals to ensure clarity, rigor, and alignment with organizational priorities; (2) establishment of a dedicated HB-HTA team - the Impact Assessment, Program Evaluation, and Implementation Research team; and (3) targeted training programs to build capacity among clinical and managerial staff. Evaluation of the framework included formative feedback from proposers and senior leaders, surveys of participant satisfaction, and qualitative interviews.</p><p><strong>Results: </strong>Between 2023 and 2024, SGH piloted and scaled the HB-HTA framework, reviewing 15 proposals exceeding USD $40 million across domains, including artificial intelligence, robotics, diagnostics, and therapeutic devices. Training workshops engaged 55 participants with high Net Promoter Scores (≥50 percent), while surveys of senior leadership showed that 91 percent were satisfied or very satisfied with the process. Qualitative feedback highlighted improved strategic alignment, transparency, and confidence in decision-making.</p><p><strong>Conclusions: </strong>SGH's experience demonstrates that embedding HB-HTA requires deliberate organizational design, leadership commitment, and stakeholder engagement. By combining concise narrative proposals with independent in-house assessments, hospitals can strengthen governance, foster accountability, and support value-driven innovation. This model offers a practical roadmap for institutions seeking to formalize HB-HTA within their decision-making processes.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e9"},"PeriodicalIF":3.0,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12902163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating international collaboration on horizon scanning for pharmaceuticals: developing key performance indicators for the international horizon scanning initiative.","authors":"Brenda Leeneman, Hedwig M Blommestein, Diana M J Delnoij, Maureen P M H Rutten-van Mölken","doi":"10.1017/S0266462325103358","DOIUrl":"10.1017/S0266462325103358","url":null,"abstract":"<p><strong>Introduction: </strong>Many European countries independently conduct horizon scanning activities. However, the costs, time, and resources required can be prohibitive. To address this, the International Horizon Scanning Initiative (IHSI) was launched in 2019. IHSI aims to facilitate decision-makers and payers in negotiating fair prices and preparing for potentially disruptive pharmaceuticals. IHSI developed the Joint Horizon Scanning Database, a repository of pharmaceuticals expected to enter the European market, and initiated a series of High Impact Reports (HIRs) to highlight pharmaceuticals that have the potential to significantly impact healthcare systems. This paper outlines the development of key performance indicators (KPIs) that can be used to evaluate IHSI's work.</p><p><strong>Results: </strong>In close collaboration with representatives from IHSI member countries and its Executive Committee, the following KPIs were developed: \"Number of IHSI member countries\", \"Embedding of IHSI in national health technology assessment procedures\", \"Database coverage\", \"Data completeness\", \"Data timeliness\", \"Accuracy of identifying disruptive pharmaceuticals\", \"Accuracy of identifying non-disruptive pharmaceuticals\", \"Use of HIRs in preparing for disruption to the healthcare system\", and \"Use of HIRs in price negotiations and financial arrangements\". Among these, \"Accuracy of identifying disruptive pharmaceuticals\" was considered most important, followed by \"Data timeliness\" and \"Data completeness\". Additionally, based on consultations with nonmember countries, strategies for improvement were identified should the KPIs reveal areas for improvement. These include involving patients in the selection of pharmaceuticals and conducting reputation surveys alongside measuring KPIs. While the KPIs and strategies for improvement are specific to IHSI, they can be tailored to support other (international) horizon scanning initiatives.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":" ","pages":"e10"},"PeriodicalIF":3.0,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12902162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}